Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Judith N. Steenbergen"'
Autor:
Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg, Anita F. Das, Marla Curran, Amy Manley, Evan Tzanis, Paul C. McGovern
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss , Pp 501-509 (2021)
Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (
Externí odkaz:
https://doaj.org/article/86f71153138b4a8c861b7b0a6e1e71ba
Autor:
Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f512cb865e5b1e50a1aff17b6dce35ce
https://doi.org/10.1128/aac.02213-21
https://doi.org/10.1128/aac.02213-21
Autor:
Eliana S. Armstrong, Janelle A. Mikulca, Daniel J. Cloutier, Caleb A. Bliss, Judith N. Steenbergen
Publikováno v:
BMC Infectious Diseases, Vol 16, Iss 1, Pp 1-6 (2016)
Abstract Background Fluoroquinolones are a guideline-recommended therapy for complicated urinary tract infections, including pyelonephritis. Elevated drug concentrations of fluoroquinolones in the urine and therapy with high-dose levofloxacin are bel
Externí odkaz:
https://doaj.org/article/d8ad02f39611496d91cd976cefa11988
Autor:
Oasis Investigators, Elliot Shin, Anita Das, Lynne Garrity-Ryan, William O'Riordan, Amy Manley, Paul C. McGovern, Judith N. Steenbergen, Evan Loh, Alissa Sirbu, Paul B. Eckburg, Evan Tzanis, Carrie Cardenas
Publikováno v:
The Lancet Infectious Diseases. 19:1080-1090
Summary Background Pathogen resistance and safety concerns limit oral antibiotic options for the treatment of acute bacterial skin and skin structure infections (ABSSSI). We aimed to compare the efficacy and safety of once-daily oral omadacycline, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd8fae8b189c6a97cb4bc520f34af78
https://doi.org/10.1016/s1473-3099(19)30275-0
https://doi.org/10.1016/s1473-3099(19)30275-0
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd8c7e74622bf15e071a75ce0771ddf
https://doi.org/10.1093/cid/ciz395
https://doi.org/10.1093/cid/ciz395
Autor:
Evan Tzanis, Amy Manley, Paul C. McGovern, George Sakoulas, Paul B. Eckburg, Judith N. Steenbergen, Fredrick M. Abrahamian, Anita Das
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. Methods We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61a1bc9f68927a397485753f71732d5
http://europepmc.org/articles/PMC6669297
http://europepmc.org/articles/PMC6669297
Autor:
Evan Loh, Joven Gonong, Anita Das, Monica Popescu, Judith N. Steenbergen, Roman Stets, Paul C. McGovern, Andrzej Madej, Paul B. Eckburg, Amy Manley, Evan Tzanis, William Nseir, Ismail Mitha, Lynne Garrity-Ryan, Courtney Kirsch
Publikováno v:
New England Journal of Medicine. 380:517-527
Background Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is acti...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43da7f19c0085d20cc1d10bcfcd479c8
https://doi.org/10.1056/nejmoa1800201
https://doi.org/10.1056/nejmoa1800201
Autor:
Corina G. Heidrich, Sanya Mitova, Andreas Schedlbauer, Sean R. Connell, Paola Fucini, Judith N. Steenbergen, Christian Berens
Publikováno v:
Antibiotics, Vol 5, Iss 4, p 32 (2016)
Omadacycline is an aminomethylcycline antibiotic with potent activity against many Gram-positive and Gram-negative pathogens, including strains carrying the major efflux and ribosome protection resistance determinants. This makes it a promising candi
Externí odkaz:
https://doaj.org/article/d445c41d292542c98e6f16a19e00af96
Autor:
Amy Manley, Courtney Kirsch, Paul C. McGovern, Antoni Torres, Lynne Garrity-Ryan, Anita Das, Judith N. Steenbergen, Marla Curran, Paul B. Eckburg, Evan Tzanis
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss, Pp 501-509 (2021)
Objective Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8afb5eb49121a256514cf1f9fd60596
https://pubmed.ncbi.nlm.nih.gov/33484864
https://pubmed.ncbi.nlm.nih.gov/33484864
Autor:
Judith N. Steenbergen, Scott A. Van Wart, Elizabeth A Lakota, M Courtney Safir, Evan Tzanis, Sujata M. Bhavnani, Lawrence V. Friedrich, Christopher M. Rubino, Michael Trang, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline, a novel aminomethylcycline antibiotic with activity against Gram-positive and -negative organisms, including tetracycline-resistant pathogens, received FDA approval in October 2018 for the treatment of patients with acute bacterial skin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bdb94e29135a314464f2ea5f88dfdde
http://europepmc.org/articles/PMC7318031
http://europepmc.org/articles/PMC7318031